The invention provides stable aqueous pharmaceutical formulations comprising the therapeutic antibody obinutuzumab (GA101), trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. Particularly, the present invention provides antibody formulations with a higher concentration of protein relative to trehalose resulting in a decreased risk of soluble aggregate and trailing edge dimer (TED). Specifically, a weight ratio of the antibody obinutuzumab to trehalose of 1.65-4.95 is found to decrease aggregation and improve stability of the antibody formulation. The invention also provides methods for making such formulations and methods of using such formulations. In the past years, advances in biotechnology have made it possible to produce a variety of proteins for pharmaceutical applications using recombinant DNA techniques.
